In FSGS, podocytes are damaged, like a net with torn holes, allowing protein to leak into the urine, creating a harmful ...

We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® ...

We recently published 10 Stocks With Easy 20-40% Gains. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the last week’s ...

Travere Therapeutics (NASDAQ:TVTX) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...

Discover key Q3 2025 earnings insights for Travere Therapeutics, including FILSPARI sales growth, FDA milestones, and outlook for rare kidney ...

Fintel reports that on November 4, 2025, Piper Sandler maintained coverage of Travere Therapeutics (NasdaqGM:TVTX) with a ...

Travere Therapeutics' stock has been volatile due to Filspari's failed Phase 3 trials, but a full FDA approval is possible next week that could boost its share price. Despite setbacks, Filspari's ...

4 analysts have expressed a variety of opinions on Travere Therapeutics (NASDAQ:TVTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) shares are trading higher on Wednesday after the company announced that it was informed by the FDA that an advisory committee is no longer needed following ...